The new modifier was introduced in 2022 to allow extra weight to be given to medicines that address severe diseases. It replaced a previous modifier that only allowed extra weight to be given for medicines to treat end-of-life conditions.
NICE has been monitoring the use of the severity modifier and presented a review to its Board. The review showed:
- Where the new severity weighting has been used there has been a higher proportion of positive recommendations (84.4%) compared with the end-of-life modifier (82.7%)…
